Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.35 |
| ▸ | TDO2 | P48775 | 2/20 | 0.34 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2190665 | 0.84 | EGFR (0.48) | EGFRPIK3CDPIK3CAPDGFRBPDGFRA | |
| SCHEMBL27918893 | 0.77 | EGFR (0.52) | EGFRPIK3CDPIK3CAPDGFRBPDGFRA | |
| SCHEMBL31753984 | 0.77 | EGFR (0.43) | EGFRPIK3CDPIK3CAPDGFRBPDGFRA | |
| SCHEMBL25065372 | 0.77 | EGFR (0.43) | EGFRPIK3CDPIK3CAPDGFRBPDGFRA | |
| SCHEMBL8874014 | 0.76 | EGFR (0.58) | EGFRPIK3CDPIK3CATDO2IMPDH2 | |
| Hydroquinone SCHEMBL8878778 | 0.74 | EGFR (0.52) | EGFRPIK3CDPIK3CAPDGFRBPDGFRA | |
| SCHEMBL3892773 | 0.73 | EGFR (0.43) | EGFRPIK3CDPIK3CAPDGFRBPDGFRA | |
| SCHEMBL24875916 | 0.73 | EGFR (0.40) | EGFRPIK3CDPIK3CAIMPDH2FGFR4 | |
| SCHEMBL24253518 | 0.73 | EGFR (0.40) | EGFRPIK3CDPIK3CAIMPDH2 | |
| SCHEMBL4728705 | 0.73 | EGFR (0.51) | EGFRPDGFRBPDGFRAFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | EGFR 4860/4885PIK3CD 2615/4885PIK3CA 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.